Gilead Sciences Inc

Price Chart

Risk-Adjusted Performance

Also Listed On

Gilead Sciences Inc (GIS) Price Performance

Gilead Sciences Inc (GIS) trades on XETRA (Frankfurt) in EUR. The company is classified in the Healthcare sector under the Drug Manufacturers - General industry. The stock currently trades at EUR118.10, down 0.37% from the previous close.

Over the past year, GIS has traded between a low of EUR84.35 and a high of EUR131.38. The stock has gained 22.6% over this period. It is currently 9.4% below its 52-week high.

Gilead Sciences Inc has a market capitalization of $157.66B, with a price-to-earnings ratio of 21.60 and a dividend yield of 2.50%.

About Gilead Sciences Inc

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.